EN DE
Watch Avecho Biotechnology Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Avecho Biotechnology Ltd (AVE) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Avecho Biotechnology Ltd stock A$0.01, price A$0.01, that is 16.7% below the price, quality 39 out of 100. Rating: overvalued. Calculated from audited financials with 4 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare AU · ISIN AU0000047441

AB Avecho Biotechnology Ltd logo Thin data Nov 9, 2026

Avecho Biotechnology Ltd

AVE · AU
Expensive, weak quality

Our calculation puts a fair price 17% below what the stock costs today.

Generates free cash flow
Mixed Growth (revenue 5y +26.3 %/yr in AUD)
Revenue last quarter 89% below a year ago.
Fair value A$0.0100 · Overvalued
Quality 39/100
Trails peers (1/8)
Narrow moat 10/100 · thin data
Thin data
⚠ Dilution
Watch Avecho Biotechnology Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

A$0.0250 A$0.0020 Fair Value A$0.0100 Mar 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.

How to read this chart

60‑month range A$0.0020 – A$0.0250 · fair‑value band A$0.0100 – A$0.0110 · the A$0.0120 price screens above the A$0.0100 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.

Follow Avecho Biotechnology in your weekly email

Every Wednesday you see whether Avecho Biotechnology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments.

Show moreShow less

The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations. Its human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches.

In addition, the company develops pharmaceutical products; oral, topical, and edible pharmaceutical cannabinoid products, including a cannabidiol TPM soft-gel capsule in Phase III clinical trial for the treatment of insomnia; and non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals.

The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 and is based in Clayton, Australia.

Stock analysis

Avecho Biotechnology Ltd (AVE) currently trades at A$0.0120, while our model-based Fair Value estimate is A$0.0100, 17% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of A$0.0100 per share, and 0 of the 3 models we run sit above the A$0.0120 price.

Bear case: the DCF Models group reads lowest at A$0.0100, and 3 of the 3 models stay below the price. Data coverage for this calculation is low.

Scenario range: A$0.0100 (bear) to A$0.0110 (bull), the price of A$0.0120 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Avecho Biotechnology Ltd reported revenue of A$1.2M in FY2025 versus A$794K in FY2021, a compound +11.8%/yr. Reported net income was −A$4.4M in FY2025.

Key figures

Market cap A$54.1M (≈ $37.3M) Micro · P/S ratio 73.4 · Return on equity −268% · Return on assets (EBIT) −85.0% (5-year average) · Operating margin −3,145% · Revenue (TTM) A$737K · Revenue growth (YoY) −89.4% · Free cash flow A$1.1M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 52% below its 52-week high and 118% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −17%, AVE screens richer than that median.

Fair Value models

Bear A$0.0100 Fair Value A$0.0100 Bull A$0.0110
Price A$0.0120 · Downside -16.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF A$0.0100 A$0.0100 A$0.0200 74
Growth DCF A$0.0100 A$0.0100 A$0.0200 72
5Y Revenue Exit n/a n/a A$0.0100 65
All 4 models by family
DCF Models
FCF DCF A$0.0100 A$0.0100 A$0.0200 74
5Y Revenue Exit n/a n/a A$0.0100 65
10Y Revenue Exit n/a A$0.0100 A$0.0100 61
Growth DCF
Growth DCF A$0.0100 A$0.0100 A$0.0200 72

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 39/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 4
How much profit the company makes from its sales and capital
Quality Growth 38
Are margins and returns getting better?
Cashflow 100
Do the profits arrive as real cash?
Financial strength 55
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 21
How calm the share price moves, does not count
Price momentum 46
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 67
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 59/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+9.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.3%
Start year 2020 (pandemic). Over 10 years: −5.5% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−880.6% (2020) → −485.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+21.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Australia: IMF forecast 3.0% a year to 2030, 2.9% from 2016 to 2025) that is about +18.4% a year for the price.

AVE screens overvalued: fair value 17% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Avecho Biotechnology Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 39 · Below median
Fair Value upside −16.7% · Above median
Profitability
Return on assets −62.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −89.4% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 34.68× · Priciest 25%
P/S (12 months) 73.37× · Priciest 25%
Price / free cash flow (fiscal year) 49.0× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)11 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs AVE
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs AVE
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs AVE
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs AVE
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs AVE
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs AVE
argenx SE ARGX $927.21 $908.40 −2% vs AVE
CSL Limited CSL A$200.77 A$183.04 −9% vs AVE
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs AVE
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs AVE

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Avecho Biotechnology Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Avecho Biotechnology Ltd Fair Value". https://www.fairvalue-calculator.com/stock/AVE

Frequently asked questions

Is Avecho Biotechnology Ltd (AVE) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of A$0.0100 versus a price of A$0.0120, about 17% lower (overvalued).
What is the fair value of AVE?
Our model-based fair value for Avecho Biotechnology Ltd is A$0.0100 (as of Nov 9, 2026), built from audited fundamentals. The current price: A$0.0120.
What is the quality score of AVE?
Avecho Biotechnology Ltd has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Avecho Biotechnology Ltd (AVE)?
Our model-based price target is the fair value of A$0.0100 (as of Nov 9, 2026) from 4 valuation models. Cautious scenario A$0.0100, optimistic scenario A$0.0110. It is a calculation from audited fundamentals, not an analyst target.
What is the Avecho Biotechnology Ltd stock forecast for 2026?
Our models put fair value at A$0.0100, about 17% lower versus a price of A$0.0120 (overvalued). Cautious scenario A$0.0100, optimistic scenario A$0.0110. The calculation is refreshed regularly with new filings.
What is the revenue of Avecho Biotechnology Ltd (AVE)?
Avecho Biotechnology Ltd reported trailing-twelve-month revenue of about A$737K (latest available figure, as of Nov 9, 2026).
What growth is priced into Avecho Biotechnology Ltd (AVE)?
For today's price to be fair in a discounted-cash-flow model, Avecho Biotechnology Ltd would have to grow free cash flow by +21.9 % per year for five years (discount rate 10.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +26.3 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of AVE use?
Our models discount Avecho Biotechnology Ltd at 10.1 %: a base by market capitalisation (nano), damped by beta 1.27, country premium for Australia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Avecho Biotechnology Ltd that is +21.9 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.1 %) and the same formula as our fair value.
How much growth has Avecho Biotechnology Ltd (AVE) delivered so far?
Over the past 5 years revenue at Avecho Biotechnology Ltd grew +26.3 % a year. The price currently implies free-cash-flow growth of +21.9 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Avecho Biotechnology Ltd (AVE) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Avecho Biotechnology Ltd (+21.9 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Avecho Biotechnology Ltd (AVE)?
The free-cash-flow yield on the price is 2.47 %: that much free cash flow Avecho Biotechnology Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Avecho Biotechnology Ltd (AVE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Avecho Biotechnology Ltd it is A$0.0100 per share (as of Nov 9, 2026), against a price of A$0.0120. It is the blended result of 4 valuation models in 2 families (DCF Models, Growth DCF).
Is Avecho Biotechnology Ltd stock overvalued or undervalued in 2026?
As of Nov 9, 2026, AVE trades above its calculated fair value: price A$0.0120, fair value A$0.0100, a gap of about −17% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AVE?
No. The price is what the market pays today (A$0.0120); the fair value is what the company's own numbers justify (A$0.0100). For Avecho Biotechnology Ltd the two are A$0.0020 per share apart. That gap is exactly why we show both numbers side by side.
How much is Avecho Biotechnology Ltd worth?
The market values Avecho Biotechnology Ltd at about A$54.1M (market capitalisation, as of Nov 9, 2026). Per share that is A$0.0120; our models calculate a fair value of A$0.0100 per share.
What do the bullish and bearish scenarios say about AVE?
Our models span a range for Avecho Biotechnology Ltd: cautious scenario A$0.0100, base A$0.0100, optimistic A$0.0110 per share (as of Nov 9, 2026, price A$0.0120). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Avecho Biotechnology Ltd (AVE)?
Balance-sheet figures for Avecho Biotechnology Ltd (as of Nov 9, 2026): return on equity −268.2%. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is AVE from its 52-week high?
Avecho Biotechnology Ltd trades at A$0.0120, about 52% below its 52-week high of A$0.0250 and 118% above the low of A$0.0055 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0100 is for.
Which stocks are comparable to Avecho Biotechnology Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Avecho Biotechnology Ltd stock attractive at the current price?
The data as of Nov 9, 2026: price A$0.0120, calculated fair value A$0.0100 (−17%), Quality Score 39/100, from 4 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AVE calculated?
We run Avecho Biotechnology Ltd through 4 models from 2 families: DCF Models, Growth DCF. Every model gets the same audited fundamentals; the fair value of A$0.0100 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Avecho Biotechnology Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Avecho Biotechnology Ltd (AVE)?
The closing price on Nov 9, 2026 was A$0.0120. Our model-based fair value is A$0.0100, about 17% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Avecho Biotechnology Ltd right now?
The price sits above even our optimistic bull case (A$0.0110). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. The models converge in a tight band (A$0.0100 to A$0.0110), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Avecho Biotechnology Ltd

How large is the market capitalisation of Avecho Biotechnology Ltd (AVE)?
The market capitalisation of Avecho Biotechnology Ltd is A$54.1M (≈ $37.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Avecho Biotechnology Ltd (AVE)?
The price-to-sales ratio of Avecho Biotechnology Ltd is 73.4 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the return on equity of Avecho Biotechnology Ltd (AVE)?
The return on equity (ROE) of Avecho Biotechnology Ltd is −268% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Avecho Biotechnology Ltd (AVE)?
On an EBIT basis the return on assets of Avecho Biotechnology Ltd is −85.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Avecho Biotechnology Ltd (AVE)?
The operating margin of Avecho Biotechnology Ltd is −3,145% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Avecho Biotechnology Ltd (AVE)?
Revenue at Avecho Biotechnology Ltd is growing −89.4% versus a year earlier (3y avg +3.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net cash does Avecho Biotechnology Ltd (AVE) hold?
Avecho Biotechnology Ltd holds more cash than debt, A$4.6M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Avecho Biotechnology Ltd in the live analysis

One click puts Avecho Biotechnology Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.